HapImmune™ platform

Aethon’s HapImmune™ platform: The convergence of targeted and immune therapy

The Aethon HapImmune platform, exclusively licensed to Aethon Therapeutics, is based on the novel observation by NYU researchers that when covalent inhibitors bind target proteins such as EGFR and RAS, they create drug-target peptide conjugates, called haptens, that can be presented by major histocompatibility complex (MHC), also known as human leucocyte antigen (HLA), molecules on the surface of tumor cells. In broadest terms, HapImmune is a mechanism to increase the antigenicity of any cancer-specific protein that can be targeted with any covalent drug and presented on HLA.